ArticleInfection and immunity2017
Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis.
Article in Infection and immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Effects of probiotic administration on overweight or obese children: a meta-analysis and systematic review.Journal of translational medicine · 2023Pooled it
- The Nexus of Gut Microbiome, Microbial Metabolites, and Colonization Resistance Against Enteric Pathogens.Biomolecules · 2026Review
- The Potential Anticancer Mechanisms of Probiotics: A Comprehensive Review.Probiotics and antimicrobial proteins · 2026Review
- Metabolic plasticity enables Clostridioides difficile growth in coculture with neutrophils and other mammalian cells.Anaerobe · 2025Article
- Article
- Standard mouse diets lead to differences in severity in infectious and non-infectious colitis.mBio · 2025Article
- Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.Probiotics and antimicrobial proteins · 2025Review
- Article
- Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Non-invasive treatment ofFrontiers in microbiology · 2025Article
- Article
- Current and Ongoing Developments in TargetingMicroorganisms · 2024Review
- The impact of different gastrointestinal reconstruction techniques on gut microbiota after gastric cancer surgery.Frontiers in microbiology · 2024Article
- Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review.Infectious diseases and therapy · 2023Review
- Decolonizing drug-resistantMicrobiology (Reading, England) · 2023Article
- Beneficial Bacteria Isolated from Food in Relation to the Next Generation of Probiotics.Microorganisms · 2023Review
- Probiotics: insights and new opportunities forCritical reviews in microbiology · 2023Review
- In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of RecurrentMicroorganisms · 2023Article
- Unveiling the inhibition mechanism ofFrontiers in microbiology · 2023Article
- Application of the Reuterin System as Food Preservative or Health-Promoting Agent: A Critical Review.Foods (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Integration of antibiotic and probiotic therapy has the potential to lessen the public health burden of antimicrobial-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.